{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:14:12Z","timestamp":1790853252688,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T00:00:00Z","timestamp":1708214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20194Y0053"],"award-info":[{"award-number":["20194Y0053"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004921","name":"Shanghai Jiao Tong University","doi-asserted-by":"publisher","award":["YG2019QNA50"],"award-info":[{"award-number":["YG2019QNA50"]}],"id":[{"id":"10.13039\/501100004921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003154"],"award-info":[{"award-number":["82003154"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372669"],"award-info":[{"award-number":["82372669"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.modpat.2024.100451","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T12:05:50Z","timestamp":1708085150000},"page":"100451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation"],"prefix":"10.1016","volume":"37","author":[{"given":"Chan","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinze","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohua","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2548-5492","authenticated-orcid":false,"given":"Yuchen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.modpat.2024.100451_bib1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2024.100451_bib2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","article-title":"Targeting MET dysregulation in cancer","volume":"10","author":"Recondo","year":"2020","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.modpat.2024.100451_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC-current perspectives and future challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2024.100451_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"Cancer Discov"},{"issue":"1 Suppl","key":"10.1016\/j.modpat.2024.100451_bib5","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2024.100451_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","article-title":"FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations","volume":"28","author":"Mathieu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.modpat.2024.100451_bib7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s10120-015-0545-5","article-title":"MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer","volume":"19","author":"Yang","year":"2016","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2024.100451_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.modpat.2024.100451_bib9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2020.08.021","article-title":"Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing","volume":"149","author":"Li","year":"2020","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.modpat.2024.100451_bib10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2024.100451_bib11","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.3390\/curroncol28050317","article-title":"Comprehensive genomic profiling of circulating cell-free DNA distinguishes focal MET amplification from aneuploidy in diverse advanced cancers","volume":"28","author":"Kumaki","year":"2021","journal-title":"Curr Oncol"},{"issue":"21","key":"10.1016\/j.modpat.2024.100451_bib12","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-22-1321","article-title":"Bioinformatically expanded next-generation sequencing analysis optimizes identification of therapeutically relevant MET copy number alterations in >50,000 tumors","volume":"28","author":"Solomon","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.modpat.2024.100451_bib13","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/2767-9764.CRC-22-0438","article-title":"Detection of MET polysomy by next-generation sequencing and its clinical relevance for MET inhibitors","volume":"3","author":"Sun","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.modpat.2024.100451_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jtho.2016.09.116","article-title":"Responses to crizotinib can occur in high-level MET-amplified non-small cell lung cancer independent of MET exon 14 alterations","volume":"12","author":"Caparica","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2024.100451_bib15","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.modpat.2024.100451_bib16","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2021.02.010","article-title":"Crizotinib in patients with MET-amplified NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"31","key":"10.1016\/j.modpat.2024.100451_bib17","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non\u2013small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"9, Supplement","key":"10.1016\/j.modpat.2024.100451_bib18","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/j.jtho.2022.07.823","article-title":"EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC post-osimertinib","volume":"17","author":"Ahn","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.modpat.2024.100451_bib19","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/1078-0432.CCR-22-3318","article-title":"Randomized trial of tepotinib plus gefitinib versus chemotherapy in EGFR-mutant NSCLC with EGFR inhibitor resistance due to MET amplification: INSIGHT final analysis","volume":"29","author":"Liam","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.modpat.2024.100451_bib20","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non\u2013small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2024.100451_bib21","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.modpat.2024.100451_bib22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.18.00177","article-title":"Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"37","author":"Lai","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2024.100451_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40164-021-00245-y","article-title":"MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors","volume":"10","author":"Peng","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2024.100451_bib24","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2018.08.008","article-title":"c-MET overexpression as a poor predictor of MET amplifications or exon 14 mutations in lung sarcomatoid carcinomas","volume":"13","author":"Mignard","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.modpat.2024.100451_bib25","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtho.2019.06.009","article-title":"MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the lung cancer mutation consortium","volume":"14","author":"Guo","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2024.100451_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/JTO.0b013e318241655f","article-title":"c-MET\/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas","volume":"7","author":"Tsuta","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.modpat.2024.100451_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.lungcan.2020.01.005","article-title":"Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer","volume":"141","author":"Yoshimura","year":"2020","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2024.100451_bib28","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/bjc.2011.298","article-title":"MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines","volume":"105","author":"Arriola","year":"2011","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.modpat.2024.100451_bib29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s41379-022-01076-w","article-title":"Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma","volume":"35","author":"Xiang","year":"2022","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2024.100451_bib30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtho.2020.11.017","article-title":"Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy","volume":"16","author":"Kron","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"18","key":"10.1016\/j.modpat.2024.100451_bib31","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.18632\/oncotarget.28045","article-title":"Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver","volume":"12","author":"Domenech","year":"2021","journal-title":"Oncotarget"},{"issue":"15_suppl","key":"10.1016\/j.modpat.2024.100451_bib32","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1200\/JCO.2021.39.15_suppl.9021","article-title":"Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp)","volume":"39","author":"Le","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2024.100451_bib33","article-title":"MET amplification and efficacy of nivolumab in patients with NSCLC","volume":"2","author":"Yoshimura","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"11","key":"10.1016\/j.modpat.2024.100451_bib34","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1158\/2159-8290.CD-20-1500","article-title":"MET amplification attenuates lung tumor response to immunotherapy by inhibiting STING","volume":"11","author":"Zhang","year":"2021","journal-title":"Cancer Discov"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224000310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395224000310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T02:12:42Z","timestamp":1736388762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395224000310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0893395224000310"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100451","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the Significance of MET Focal Amplification in Lung Cancer: Integrative NGS, FISH, and IHC Investigation","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2024.100451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}],"article-number":"100451"}}